DE60309057D1 - Azabicycloderivate als antagonisten des muscarinischen rezeptors - Google Patents

Azabicycloderivate als antagonisten des muscarinischen rezeptors

Info

Publication number
DE60309057D1
DE60309057D1 DE60309057T DE60309057T DE60309057D1 DE 60309057 D1 DE60309057 D1 DE 60309057D1 DE 60309057 T DE60309057 T DE 60309057T DE 60309057 T DE60309057 T DE 60309057T DE 60309057 D1 DE60309057 D1 DE 60309057D1
Authority
DE
Germany
Prior art keywords
antagonists
azabicycloderivates
relates
compounds
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60309057T
Other languages
English (en)
Other versions
DE60309057T2 (de
Inventor
Mohammad Salman
Anita Mehta
Kumara Sarma
Jayram Shetty
Sankaranarayanan Dharmarajan
Naresh Kumar
Viswanatham Silamkoti
Anita Chugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Application granted granted Critical
Publication of DE60309057D1 publication Critical patent/DE60309057D1/de
Publication of DE60309057T2 publication Critical patent/DE60309057T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60309057T 2002-07-08 2003-04-11 Azabicycloderivate als antagonisten des muscarinischen rezeptors Expired - Fee Related DE60309057T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2002/002663 WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WOPCT/IB02/02663 2002-07-08
PCT/IB2003/001367 WO2004005252A1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
DE60309057D1 true DE60309057D1 (de) 2006-11-23
DE60309057T2 DE60309057T2 (de) 2007-04-12

Family

ID=30011691

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60230683T Expired - Fee Related DE60230683D1 (de) 2002-07-08 2002-07-08 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
DE60309057T Expired - Fee Related DE60309057T2 (de) 2002-07-08 2003-04-11 Azabicycloderivate als antagonisten des muscarinischen rezeptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60230683T Expired - Fee Related DE60230683D1 (de) 2002-07-08 2002-07-08 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat

Country Status (20)

Country Link
US (2) US7399779B2 (de)
EP (2) EP1546099B1 (de)
JP (2) JP2006502985A (de)
CN (2) CN1668585A (de)
AT (2) ATE419236T1 (de)
AU (2) AU2002345266B2 (de)
BR (2) BR0215801A (de)
CA (2) CA2492121A1 (de)
CY (1) CY1105879T1 (de)
DE (2) DE60230683D1 (de)
DK (1) DK1551803T3 (de)
EA (3) EA200500173A1 (de)
ES (1) ES2274275T3 (de)
HK (2) HK1079783A1 (de)
MX (2) MXPA05000434A (de)
NZ (2) NZ537584A (de)
PT (1) PT1551803E (de)
SI (1) SI1551803T1 (de)
WO (2) WO2004004629A2 (de)
ZA (1) ZA200500951B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
JP2006518707A (ja) 2002-12-10 2006-08-17 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしての３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
EP1618091A1 (de) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren
AU2004228452A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
GEP20104959B (en) * 2003-10-14 2010-04-26 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006003587A2 (en) * 2004-07-01 2006-01-12 Ranbaxy Laboratories Limited Solid oral dosage forms of azabicyclo derivatives
WO2006016245A1 (en) * 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006032994A2 (en) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1796667A2 (de) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinische rezeptor-antagonisten
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
JP2009512676A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
EP1968980A1 (de) 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Muscarin-rezeptor-antagonisten
EA200801591A1 (ru) 2005-12-30 2008-12-30 Рэнбакси Лабораториз Лимитед Антагонисты мускаринового рецептора
US20100152269A1 (en) * 2006-12-21 2010-06-17 Ranbaxy Laboratories Limited Modified-release formulations of azabicyclo derivatives
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2018136437A2 (en) * 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
EP3823604A4 (de) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System Verbindungen als inhibitoren der indolamin-2,3-dioxygenase und/oder tryptophan-dioxygenase
CN111317754B (zh) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 一种北豆根总碱的制备方法及应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
NL267508A (de) 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
RU2049777C1 (ru) 1989-08-16 1995-12-10 Пфайзер Инк. Азабицикло-хинолон-карбоновые кислоты или их фармацевтически приемлемые кислотно-аддитивные соли и промежуточные продукты для их получения
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
FR2659323B1 (fr) 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
JPH0492921A (ja) 1990-08-03 1992-03-25 Fujitsu Ltd 指数関数演算器
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JPH0635958A (ja) 1992-07-14 1994-02-10 Hitachi Ltd 語句検索方法
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
ATE152302T1 (de) 1993-02-24 1997-05-15 Siemens Ag Sperrwandler-schaltnetzteil mit einem halbleiterschaltelement geringer spannungsfestigkeit
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0823423B1 (de) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituierte piperidinderivate
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
WO1997045414A1 (fr) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. Derives de piperidine a disubstitution en positions 1,4
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
EP0909172A4 (de) 1996-07-01 1999-06-09 Sepracor Inc Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat
WO1998000133A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate
EP0909163A4 (de) 1996-07-01 1999-06-09 Sepracor Inc Verfahren und mittel zur behandlung der harninkontinenz unter hauptsaechlicher verwendung des (s,r)-glycopyrrolat enantiomers
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
WO1998053814A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
CA2392028C (en) 1999-12-07 2009-08-18 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
YU89002A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil-laktami i njihova primena kao antagonista za muskarinske receptore
YU88902A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil laktami i njihova primena kao antagonista muskarinskih receptora
EP1294697A1 (de) 2000-06-14 2003-03-26 Muscagen Limited 1,2,3,5-tetrahydrobenzo[c]azepin-4-on derivate mit muskarinantagonistischer wirkung
PT1300407E (pt) 2000-06-27 2004-05-31 S A L V A T Lab Sa Compostos carbamatos derivados de arilalquilaminas
WO2002004402A1 (fr) 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Derives d'ester
BR0116450A (pt) 2000-12-22 2003-09-30 Almirall Prodesfarma Ag Composto, processos para a preparação de um carbamato, e para produzir um sal, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, produto de combinação
BR0116624A (pt) 2000-12-28 2003-12-23 Almirall Prodesfarma Ag Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
EP1438309A1 (de) 2001-10-17 2004-07-21 Ucb, S.A. Chinuclidine-derivate, verfahren zu ihrer herstellung und ihre verwendung als m2 und/oder m3 muskarinerge inhibitoren
CA2468691C (en) 2001-12-03 2011-03-08 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
EP1453806B1 (de) 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Aminotetralinderivate, antagonisten von muscarinrezeptoren
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (de) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ¬3.1.0 hexan-derivate als muscarinische rezeptor-antagonisten
EP1534675B1 (de) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluor- und sulfonylaminohaltige, 3,6-disubstituierte azabicyclo¬3.1.0 hexanderivate als muscarinrezeptorantagonisten
JP2006518707A (ja) 2002-12-10 2006-08-17 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしての３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
WO2004056810A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1594871A1 (de) 2003-02-07 2005-11-16 Ranbaxy Laboratories Limited Substituierte azabicyclohexan-derivate als muscarinische rezeptor-antagonisten
EP1618091A1 (de) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BR0318242A (pt) 2003-04-10 2006-04-04 Ranbaxy Lab Ltd derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
FR2855805B1 (fr) 2003-06-06 2005-08-05 Vallourec Vitry Element de structure pour vehicule, capable d'un meilleur comportement aux chocs
WO2005092341A1 (en) 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
EP1796667A2 (de) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinische rezeptor-antagonisten
WO2006064304A1 (en) 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists

Also Published As

Publication number Publication date
EA200501595A1 (ru) 2006-06-30
ZA200500951B (en) 2006-07-26
PT1551803E (pt) 2007-01-31
BR0215801A (pt) 2005-05-10
EP1551803A1 (de) 2005-07-13
CN1668585A (zh) 2005-09-14
ATE419236T1 (de) 2009-01-15
CA2491998A1 (en) 2004-01-15
CN1681784A (zh) 2005-10-12
EA009942B1 (ru) 2008-04-28
AU2002345266B2 (en) 2009-07-02
EA200500172A1 (ru) 2005-08-25
US20070004791A1 (en) 2007-01-04
EP1546099A4 (de) 2006-08-02
BR0312572A (pt) 2005-05-10
US20060111425A1 (en) 2006-05-25
AU2003226579B2 (en) 2009-01-22
EA200500173A1 (ru) 2005-08-25
HK1079783A1 (en) 2006-04-13
ATE342253T1 (de) 2006-11-15
DE60230683D1 (de) 2009-02-12
CN100519526C (zh) 2009-07-29
EP1551803B1 (de) 2006-10-11
DE60309057T2 (de) 2007-04-12
SI1551803T1 (sl) 2007-02-28
CY1105879T1 (el) 2011-02-02
ES2274275T3 (es) 2007-05-16
JP2005535655A (ja) 2005-11-24
AU2003226579A1 (en) 2004-01-23
WO2004004629A3 (en) 2004-05-21
DK1551803T3 (da) 2007-02-19
HK1082728A1 (en) 2006-06-16
WO2004004629A2 (en) 2004-01-15
EP1546099A2 (de) 2005-06-29
JP2006502985A (ja) 2006-01-26
MXPA05000434A (es) 2005-04-19
CA2492121A1 (en) 2004-01-15
US7399779B2 (en) 2008-07-15
EP1551803B8 (de) 2006-12-13
MXPA05000435A (es) 2005-04-19
NZ537584A (en) 2006-07-28
EA007932B1 (ru) 2007-02-27
AU2002345266A1 (en) 2004-01-23
EP1546099B1 (de) 2008-12-31
NZ537585A (en) 2006-07-28
WO2004005252A1 (en) 2004-01-15
US7544708B2 (en) 2009-06-09

Similar Documents

Publication Publication Date Title
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
TW200505903A (en) CGRP receptor antagonists
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
EP1615914A4 (de) Cgrp-rezeptorantagonisten
IL182317A0 (en) Cgrp receptor antagonists
EP1804919A4 (de) Cgrp-rezeptorantagonisten
HK1079787A1 (zh) 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists
EP1802372A4 (de) Cgrp-rezeptorantagonisten
WO2006035282A3 (en) Muscarinic receptor antagonists
ATE400553T1 (de) 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
ATE386738T1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
WO2006032994A3 (en) Muscarinic receptor antagonists
WO2007007281A3 (en) Muscarinic receptor antagonists
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: RANBAXY LABORATORIES, LTD., GURGAON, IN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee